Omnicell Inc stock (US6821321088): OMCL gains on Nasdaq as short interest edges above 6 percent

Omnicell Inc shares advanced on Nasdaq at the start of the week, with the stock moving higher while short interest climbed to just over 6 percent of free float in May 2026.

Omnicell Inc shares traded higher on the Nasdaq on Monday, with the stock closing at USD 44.72 on 05/29/2026, up 3.71 percent for the session, according to MarketBeat as of 05/29/2026. The move came as updated data showed that as of 05/15/2026, short interest in the United States-listed medication management specialist stood at about 2.68 million shares, representing roughly 6.07 percent of the public float. In extended trading on the same day, Omnicell Inc changed hands at around USD 44.88 on Nasdaq, underscoring continued activity in the United States home market for the stock.

The stock price action keeps Omnicell Inc squarely in focus for U.S. investors watching healthcare technology names on Nasdaq, where the company trades under the ticker OMCL. While there was no fresh company press release or SEC filing on 05/29/2026, the combination of a more than 3 percent daily gain and a short interest level above 6 percent of free float may indicate that positioning in the shares is a key theme at the start of the week.

As of: 01.06.2026

By the editorial team - specialized in equity coverage.

At a glance

• Name: Omnicell Inc
• Sector/industry: Healthcare technology, pharmacy automation and medication management solutions
• Headquarters/country: Mountain View, United States
• Core markets: Hospitals, health systems and pharmacies primarily in North America with selected international deployments
• Key revenue drivers: Automation systems for medication dispensing, adherence solutions and related software and services contracts
• Home exchange/listing venue: Nasdaq (OMCL)
• Trading currency: USD

Omnicell Inc: core business model

Omnicell Inc focuses on technology-enabled medication management and automation offerings for hospitals, health systems and pharmacies, generating revenue mainly from equipment sales, recurring software licenses and service arrangements around those platforms.

What banks and research houses say about Omnicell Inc

No verified analyst coverage was identified at the time of publication.

Conclusion

Omnicell Inc started the week on a firmer footing in the United States, with the Nasdaq-listed shares advancing even as short interest hovered above 6 percent of public float as of mid-May 2026. The absence of fresh company-specific news places the focus on trading positioning and sentiment, while investors continue to monitor how the healthcare technology company executes on its pharmacy automation and medication management strategy.

Disclaimer: This article does not constitute investment advice. The comprehensive scope of this informative article was made possible through the use of a.i.. Stocks are volatile financial instruments.